| pubmed-article:19075280 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0544452 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0059985 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:19075280 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:19075280 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:19075280 | pubmed:dateCreated | 2009-2-2 | lld:pubmed |
| pubmed-article:19075280 | pubmed:abstractText | Modern combination strategies are active in chronic lymphocytic leukemia (CLL) but can have significant myelosuppression and immunosuppression that may require dose attenuation for safety. We explored a sequential treatment strategy to allow safe delivery of active agents at full doses. Previously, we studied sequential therapy with fludarabine followed by cyclophosphamide (F-->C). In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R). | lld:pubmed |
| pubmed-article:19075280 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19075280 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19075280 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19075280 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:19075280 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:BrentjensReni... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:PanageasKathe... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:GoldeDavid... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:ZelenetzAndre... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:MaslakPeterP | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:JurcicJoseph... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:ScheinbergDav... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:HeaneyMark... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:WeissMark AMA | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:NoyArielaA | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:LamannaNicole... | lld:pubmed |
| pubmed-article:19075280 | pubmed:author | pubmed-author:GencarelliAli... | lld:pubmed |
| pubmed-article:19075280 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19075280 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19075280 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:19075280 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19075280 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19075280 | pubmed:pagination | 491-7 | lld:pubmed |
| pubmed-article:19075280 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:meshHeading | pubmed-meshheading:19075280... | lld:pubmed |
| pubmed-article:19075280 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19075280 | pubmed:articleTitle | Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. | lld:pubmed |
| pubmed-article:19075280 | pubmed:affiliation | Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. | lld:pubmed |
| pubmed-article:19075280 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19075280 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19075280 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19075280 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
